Search results
Apr 22, 2024 · Some FDA reviewers, including the recently retired Janet Woodcock, have thankfully recognized the perils of a so-called type 2 error, where a drug’s benefits are overlooked and waiting patients ...
Apr 18, 2024 · September 1993 – Janet Woodcock was the Director of FDA’s Office of Therapeutics Research and Review. – REF. Why is this interesting? Woodcock was the FDA rep in 2020 that thwarted hydroxychloroquine and ivermectin’s use for COVID-19 early treatment, an act that allowed novel COVID-19 vaccines to be authorised under EUA.
Apr 17, 2024 · Executive Summary. Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Apr 4, 2024 · While Raoult's unfounded claims about hydroxychloroquine drew initial attention to his COVID-19-related work—with critics quickly noting flaws and weaknesses in his studies—his high-profile ...
Apr 24, 2024 · The group was joined by former FDA leader Janet Woodcock, M.D., who participated in the weekend-long retreat and sat down for a fireside chat in which she detailed her career path, from academia ...
Apr 8, 2024 · The medication hydroxychloroquine was touted by right-wing media figures and others as an effective treatment for covid-19. Research later showed it was not and could even pose harmful side ...
Apr 4, 2024 · Hydroxychloroquine (HCQ) use is indicated for patients with systemic lupus erythematosus (SLE). Nevertheless, reports discussing the reasons for not prescribing HCQ are limited. We identified the factors that interfere with HCQ use in patients with SLE. This observational, single-center study included data from 265 patients with SLE in 2019.
